Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’

Charafe‐Jauffret, Emmanuelle, Tarpin, Carole, Bardou, Valérie‐Jeanne, Bertucci, François, Ginestier, Christophe, Braud, Anne‐Chantal, Puig, Brigitte, Geneix, Jeannine, Hassoun, Jacques, Birnbaum, Daniel, Jacquemier, Jocelyne, Viens, Patrice·2004·The Journal of Pathology

Abstract

Inflammatory breast cancer (IBC) is a rare but very aggressive form of breast cancer. Its definition is based on clinical criteria, but a molecular definition could be useful when data are incomplete or features are missing. Recently, the identification of overexpression of E‐cadherin in IBC has improved understanding of the molecular basis of this disease. Consequently, the aim of this study was to try to determine an immunophenotypic ‘signature’ of IBC. A series of 80 cases of IBC were compared with 552 non‐IBC control cases and a model was elaborated to evaluate the probability of an inflammatory carcinoma being present in any clinical situation. Tissue microarrays (TMAs) were used to determine the immunohistochemical profile of eight proteins including E‐cadherin, EGFR, oestrogen and progesterone receptor (ER and PR), MIB1, ERBB2, MUC1, and P53. All the parameters tested were differentially expressed between IBC and control cases in univariate analysis ( p < 0.001). The five variables that were significantly associated with IBC in multivariate analysis were E − cadherin ≥ 300 [HR = 5.64 (2.92–10.87)], ER negative [HR = 3.00 (1.67–5.51)], MIB1 > 20 [HR = 3.54 (1.87–6.71)], MUC1 cytoplasmic staining [HR = 2.72 (1.49–4.96)], and ERBB2 positive 2+ or 3+ [HR = 2.46 (1.26–4.78)]. The probability that a breast cancer with this full phenotype at diagnosis was an IBC was 90.5%. If any one of the five parameters was missing, this probability dropped to 75% and was less than 50% when one, two, or three parameters were present. The 5‐year overall survival (OS) and 5‐year disease‐free survival (DFS) of patients with IBC were not significantly different from those of the non‐IBC control group that expressed four or five parameters (nIBC‐1), but this nIBC‐1 control group had a significantly worse outcome than the non‐IBC control group (nIBC‐2) with only 0–3 parameters ( p = 0.0049 for OS and p < 0.0001 for DFS). In conclusion, an immunophenotypic signature was suggested for IBC. This could help to determine the worst cases, independent of clinical criteria. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/path.1515

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 199

Metadata

Authors
Charafe‐Jauffret, E., Tarpin, C., Bardou, V., Bertucci, F., Ginestier, C., Braud, A., Puig, B., Geneix, J., Hassoun, J., Birnbaum, D., Jacquemier, J., & Viens, P.
Venue
The Journal of Pathology
Publisher
Wiley
Published
2004-02-16
Volume
202
Issue
3
Pages
265-273
ISSN
  • 0022-3417 (ISSN-L)
  • 1096-9896
OpenAlex
W2047209584
Cited by
199
References
2
FWCI
5.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. https://app.cochat.ai/papers/10.1002/path.1515
The paper
Charafe‐Jauffret, E., Tarpin, C., Bardou, V., Bertucci, F., Ginestier, C., Braud, A., Puig, B., Geneix, J., Hassoun, J., Birnbaum, D., Jacquemier, J., & Viens, P. (2004). Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. The Journal of Pathology. https://doi.org/10.1002/path.1515

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.